Treatment-free remission in chronic myeloid leukemia: can we identify prognostic factors?
HH Saifullah, CM Lucas - Cancers, 2021 - mdpi.com
Simple Summary Chronic myeloid leukemia (CML) is a blood cancer. Unlike other cancers
CML treatment is lifelong and many patients experience side effects. For those patients who …
CML treatment is lifelong and many patients experience side effects. For those patients who …
Chronic myeloid leukemia prognosis and therapy: criticisms and perspectives
D Russo, JV Garcia-Gutierrez, S Soverini… - Journal of Clinical …, 2020 - mdpi.com
Ph+ chronic myeloid leukemia (CML) is a clonal myeloproliferative disease whose clinical
course is characterized by progression disease from the early chronic phase (CP) to the fatal …
course is characterized by progression disease from the early chronic phase (CP) to the fatal …
Imatinib uptake into cells is not mediated by organic cation transporters OCT1, OCT2, or OCT3, but is influenced by extracellular pH
JB Mettral, N Faller, S Cruchon, L Sottas… - Drug metabolism …, 2019 - ingentaconnect.com
Background: Cancer cells undergo genetic and environmental changes that can alter
cellular disposition of drugs, notably by alterations of transmembrane drug transporters …
cellular disposition of drugs, notably by alterations of transmembrane drug transporters …
Treatment Outcomes of Nilotinib as Second Line Therapy for Chronic Myeloid Leukemia Patients in Karbala Province of Iraq
Background: Second line treatment of chronic myeloid leukemia (CML) is crucial after
imatinib therapy failure. In Iraq, nilotinib is the only available second line tyrosine kinase …
imatinib therapy failure. In Iraq, nilotinib is the only available second line tyrosine kinase …
Prognostic Implications of Sokal, Hasford, and EUTOS scores on Complete Hematologic and Early Molecular Responses in Newly Diagnosed Chronic Myeloid …
Sokal, Hasford, and EUTOS prognostic scoring systems are widely used for chronic myeloid
leukemia (CML) patients. However, whether one of these scoring systems was better …
leukemia (CML) patients. However, whether one of these scoring systems was better …
[PDF][PDF] Perbandingan Skor Sokal dan Skor Hasford terhadap Respons Terapi Imatinib Mesylate pada Pasien Leukemia Granulositik Kronis di Rumah Sakit dr
BDM Somarnam, DH Hermanto - Jurnal Penyakit Dalam …, 2019 - scholarhub.ui.ac.id
ABSTRAK Pendahuluan. Skor Sokal dan Hasford berkembang sebelum era terapi tirosine
kinase inhibitor (TKI) untuk memberikan prediksi dan prognosis hasil terapi pasien leukemia …
kinase inhibitor (TKI) untuk memberikan prediksi dan prognosis hasil terapi pasien leukemia …
[PDF][PDF] Comparison of Clinicopathological Parameters, and Treatment Responses in Younger and Older Chronic Myeloid Leukaemia Patients Treated with Imatinib.
AF Kamarudin, S Palaniappan… - Malaysian Journal of …, 2023 - medic.upm.edu.my
Introduction: Differences in baseline characteristics and response to treatment in different
age groups of patients with chronic myeloid leukaemia (CML) in resource-limited countries …
age groups of patients with chronic myeloid leukaemia (CML) in resource-limited countries …
Korelasi skor sokal terhadap respons molekuler mayor pada penderita chronic myeloid leukemia yang mendapat terapi nilotinib
M Riswan, SE Pratama, M Fuad… - Jurnal Kedokteran Syiah …, 2023 - jurnal.usk.ac.id
Chronic Myeloid Leukemia (CML) adalah penyakit mieloproliferatif dengan peningkatan
proliferasi sel induk hematopoietik seri mieloid pada berbagai stadium diferensiasi. Saat ini …
proliferasi sel induk hematopoietik seri mieloid pada berbagai stadium diferensiasi. Saat ini …
Analisis skor hasford sebagai prediktor respons molekuler mayor pada penderita chronic myeloid leukemia yang mendapat terapi nilotinib
M Riswan, I Irwandi, M Fuad… - Jurnal Kedokteran Syiah …, 2023 - jurnal.usk.ac.id
Pendahuluan: Chronic myeloid leukemia (CML) merupakan neoplasma myeloproliferative
clonal ditandai dengan ekspansi sel punca sumsum tulang pluripoten yang tidak terkendali …
clonal ditandai dengan ekspansi sel punca sumsum tulang pluripoten yang tidak terkendali …
Faktor prognostik pasien Chronic Myeloid Leukemia (CML) yang menggunakan terapi Tyrosine Kinase Inhibitor (TKI) berdasarkan skoring Sokal dan Hasford: sebuah …
RW Tendean, NMRA Rena… - Intisari Sains …, 2021 - mailgate.isainsmedis.id
Background: Tyrosine Kinase Inhibitor (TKI) therapy is known to improve overall survival in
Chronic Myeloid Leukemia (CML) patients. This research aims to assess the overall survival …
Chronic Myeloid Leukemia (CML) patients. This research aims to assess the overall survival …